Several biomarkers have been investigated in lymphoid malignancies, including the PD-L1 H-score, alterations/amplification of the 9p24.1 gene, microsatellite instability (MSI), tumor mutational burden (TMB), the density of intratumoral CD8+ T lymphocyte infiltrates, genetic alterations in MHC classes I and II, and miRNA-21, among others [120]. This evidence concerns the gene CD8A and neoplasm.